Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 557.69M P/E - EPS this Y -29.60% Ern Qtrly Grth -
Income -71.9M Forward P/E -4.91 EPS next Y -11.60% 50D Avg Chg -10.00%
Sales - PEG -0.08 EPS past 5Y - 200D Avg Chg -12.00%
Dividend N/A Price/Book 1.88 EPS next 5Y 57.50% 52W High Chg -38.00%
Recommedations 1.60 Quick Ratio 22.57 Shares Outstanding 49.63M 52W Low Chg 8.00%
Insider Own 2.96% ROA -28.91% Shares Float 22.99M Beta -
Inst Own 92.47% ROE -41.38% Shares Shorted/Prior 872.86K/842.10K Price 13.65
Gross Margin - Profit Margin - Avg. Volume 155,235 Target Price 33.83
Oper. Margin - Earnings Date - Volume 72,016 Change -1.44%
About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Mineralys Therapeutics, Inc. News
04/04/24 Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks
03/22/24 Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript
03/21/24 Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...
03/21/24 Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
03/13/24 Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024
02/08/24 Mineralys Therapeutics Announces $120 Million Private Placement Financing
01/29/24 Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference
01/17/24 Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know
01/04/24 Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
12/21/23 Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
11/27/23 Positive Signs As Multiple Insiders Buy Mineralys Therapeutics Stock
11/12/23 Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call Transcript
11/11/23 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023
11/09/23 Mineralys Therapeutics to Participate in Three Upcoming Conferences
11/07/23 Mineralys Therapeutics Inc (MLYS) Reports Q3 2023 Financials; R&D Expenses Rise Amid ...
11/07/23 Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/02/23 Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting
10/31/23 Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023
10/17/23 We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
10/13/23 Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023
MLYS Chatroom

User Image Corona_My_Sharona Posted - 04/23/24

$MLYS,,,,,, https://www.forbes.com/sites/jakezamansky/2013/08/08/the-great-vampire-squid-keeps-on-sucking/?sh=47c5415e7df8

User Image Motohead125 Posted - 04/18/24

$MLYS wtf happened here today

User Image Motohead125 Posted - 04/09/24

$MLYS starter position opened to follow and start my DD

User Image Corona_My_Sharona Posted - 04/06/24

$MLYS https://www.theguardian.com/business/andrew-clark-on-america/2009/jul/14/goldmansachs-banks

User Image Corona_My_Sharona Posted - 04/06/24

$MLYS

User Image techNICKaltrader Posted - 04/03/24

$MLYS violent move if this can turn and break 16.67... 25+

User Image Doorkey Posted - 04/02/24

$MLYS On my buy/swing list...

User Image Quantumup Posted - 04/02/24

Goldman Sachs🏁 $MLYS Buy/$30 Co's🎯HTN approach still has unmet need cuz SoC's gynecomastia/hyperkalemia effects. GS believes lorundrostat's level of eff can achieve BiC/ Co's approach4obesity-related HTN could Tx 7-8M US pts; est $2.8B WW non-risk-adj or $1.1B risk-adj peak sales:

User Image Thestocktraderhubzee Posted - 04/02/24

$MLYS Goldman Sachs Initiates Coverage On Mineralys Therapeutics with Buy Rating, Announces Price Target of $30

User Image DonCorleone77 Posted - 04/02/24

$MLYS Mineralys Therapeutics initiated with a Buy at Goldman Sachs Goldman Sachs initiated coverage of Mineralys Therapeutics with a Buy rating and $30 price target. The company's lead asset, lorundrostat, is a selective aldosterone synthase inhibitor being developed in 3/4L hypertension, which still has an unmet need due to standard of care spironolactone's gynecomastia and hyperkalemia effects, the analyst tells investors in a research note. The firm believes lorundrostat's level of efficacy can achieve best-in-class and that Mineralys' targeted approach for obesity-related hypertension settings could still treat 7M-8M targetable patients in the U.S. alone.

User Image Motohead125 Posted - 03/23/24

$MLYS stumbled upon this. Like what I'm seeing and will start a position here over the next quarter

User Image CH_Expat Posted - 03/21/24

$MLYS The more research I do, the more I am into this stock. It looks very promising. Low market cap considering the huge potential TAM. Totally underneath the retail radar. Those are the ones that got normally taken out - Turning Point, Forma and so many others while 65,982 users are raving at the $AUPH Board. CinCor was inferior in data and got bought out at 1,3b. Will add here big time if we stay in this range or drop.

User Image DonCorleone77 Posted - 03/21/24

$MLYS Mineralys Therapeutics files to sell 8.89M shares of common stock for holders

User Image DonCorleone77 Posted - 03/21/24

$MLYS Mineralys Therapeutics files $500M mixed securities shelf

User Image DonCorleone77 Posted - 03/21/24

$MLYS Mineralys Therapeutics reports Q4 EPS (61c), consensus (82c) "Throughout 2023 we accomplished key milestones that put us in a position to execute our pivotal development plan for lorundrostat for the treatment of hypertension, as well as adjacent conditions including chronic kidney disease," stated Jon Congleton, Chief Executive Officer of Mineralys Therapeutics. "In 2024, we are working towards achieving several clinical events, which we expect to expand the data package for lorundrostat. We believe aldosterone, like obesity, is a significant driver of cardiorenal metabolic conditions and our pursuit of developing an aldosterone targeted approach has the potential to impact millions of patients impacted by these conditions."

User Image Stock_Titan Posted - 03/21/24

$MLYS Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-reports-fourth-quarter-and-full-year-2023-q6za867qd7b8.html

User Image Stock_Titan Posted - 03/13/24

$MLYS Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024 https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-to-announce-fourth-quarter-and-full-year-2023-7fl2936bt19i.html

User Image CH_Expat Posted - 03/11/24

$MLYS 84 watchers. Always a good sign.

User Image Buggy233 Posted - 02/28/24

$MLYS why is this doing bad today?

User Image PlugPortal Posted - 02/26/24

$MLYS Setting up

User Image insiderbuyingselling Posted - 02/14/24

$MLYS new insider buying: 555555 shares. http://insiderbuyingselling.com/?t=MLYS

User Image RockyTSTH Posted - 02/08/24

$MLYS Mineralys Therapeutics shares are trading higher after the company announced $120 million in private placement financing

User Image MatthewMenzies Posted - 02/08/24

$MLYS $UK $IREN Analyst price target for today{} https://live-alerts-stock-trades.daytrading.network

User Image ANTHONYMOMO Posted - 02/08/24

$MLYS finishing up a base

User Image DonCorleone77 Posted - 02/08/24

$MLYS Mineralys Therapeutics to sell 8.9M shares at $13.50 in private placement Mineralys Therapeutics announced that it has entered into a securities purchase agreement with institutional accredited investors to sell securities in a private placement financing for gross proceeds of approximately $120 million, before deducting estimated fees and expenses.The financing was led by new investor TCGX and existing investor RA Capital Management, with participation from new investors OrbiMed and Venrock Healthcare Capital Partners, along with several existing investors including Samsara BioCapital and a large investment management firm. In the PIPE, Mineralys is selling an aggregate of approximately 8.9 million shares of its common stock at a price of $13.50 per share. The pre-funded warrants will have an exercise price of $0.001 per share of common stock, will be immediately exercisable and will not expire. The PIPE is expected to close on February 12, 2024....

User Image Stock_Titan Posted - 02/08/24

$MLYS Mineralys Therapeutics Announces $120 Million Private Placement Financing https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-announces-120-million-private-placement-6028uudkrs02.html

User Image CMT73 Posted - 02/05/24

$MLYS why the sudden reversal…?

User Image _www_larval_com_ Posted - 3 months ago

$SPRB 6%[-7%] $RR 4%[-7%] $PEPG -4%[20%] $MLYS 4%[15%] $FBLG 3%[-40%] most notable movement into the final minutes of trading.

User Image ChartMill Posted - 01/24/24

$RYTM, $OVID, $ALXO, $MLYS and $QCRH are the top gainers in the Russel 2000 for the day. https://www.chartmill.com/stock/stock-screener?v=3&f=ind_18&s=pt&utm_source=top_Russel_2000_gainers&utm_medium=stocktwits&utm_campaign=screen

Analyst Ratings
Goldman Sachs Buy Apr 2, 24
Credit Suisse Outperform Aug 8, 23
Credit Suisse Outperform May 16, 23
Credit Suisse Outperform Mar 16, 23
Evercore ISI Group Outperform Mar 7, 23
Wells Fargo Overweight Mar 7, 23
Credit Suisse Outperform Mar 7, 23
Guggenheim Buy Mar 7, 23
B of A Securities Buy Mar 7, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Rodman David Malcom Chief Medical Office.. Chief Medical Officer Dec 11 Option 0.54 5,018 2,710 20,069 12/12/23
Rodman David Malcom Chief Medical Office.. Chief Medical Officer Nov 03 Option 0.54 10,034 5,418 10,034 11/07/23
Congleton Jon Chief Executive Offi.. Chief Executive Officer Sep 06 Buy 12.08 2,250 27,180 1,044,818 09/08/23
Rodman David Malcom Chief Medical Office.. Chief Medical Officer Aug 10 Sell 12.93 231,716 2,996,088 08/11/23
Rodman David Malcom Chief Medical Office.. Chief Medical Officer Aug 10 Option 0.72 231,716 166,836 76,182 08/11/23
Congleton Jon Chief Executive Offi.. Chief Executive Officer Aug 11 Buy 12.89 2,000 25,780 1,040,318 08/11/23
HBM Healthcare Investments (Ca... 10% Owner 10% Owner Feb 14 Buy 16 312,500 5,000,000 3,218,106 02/16/23